JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Appendix B
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Watchman, C. J.
Right arrow Articles by Bolch, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watchman, C. J.
Right arrow Articles by Bolch, W. E.
Journal of Nuclear Medicine Vol. 46 No. 7 1171-1185
© 2005 by Society of Nuclear Medicine


Basic Science Investigations

Absorbed Fractions for {alpha}-Particles in Tissues of Trabecular Bone: Considerations of Marrow Cellularity Within the ICRP Reference Male

Christopher J. Watchman, MS1, Derek W. Jokisch, PhD2, Phillip W. Patton, PhD3, Didier A. Rajon, PhD4, George Sgouros, PhD5 and Wesley E. Bolch, PhD1,6

1 Department of Nuclear and Radiological Engineering, University of Florida, Gainesville, Florida
2 Department of Physics and Astronomy, Francis Marion University, Florence, South Carolina
3 Department of Health Physics, University of Nevada–Las Vegas, Las Vegas, Nevada
4 Department of Neurosurgery, University of Florida, Gainesville, Florida
5 Department of Radiology, Johns Hopkins University, Baltimore, Maryland
6 Department of Biomedical Engineering, University of Florida, Gainesville, Florida

{alpha}-Particles are of current interest in radionuclide therapy due to their short range and high rates of energy transfer to target tissues. Published values of {alpha}-particle absorbed fraction {phi} in the skeletal tissues, as needed for patient-specific dosimetry under the MIRD schema, do not generally account for its variation with particle energy or skeletal site. Furthermore, variations in {alpha}-particle absorbed fraction with marrow cellularity have yet to be fully considered. Methods: In this study, a 3-dimensional (3D) chord-based radiation transport model (or 3D-CBIST) is presented, which combines (a) chord-based techniques for tracking {alpha}-particles across bone trabeculae, endosteum, and marrow cavities and (b) a spatial model of the marrow tissues that explicitly considers the presence of marrow adipocytes. Chord-length distributions are taken from a 44-y male subject (ICRP [International Commission on Radiological Protection] Reference Male) and are identical to those used currently for clinical dose estimates for ß-particle emitters. Results: Values of {phi}(active marrow<-active marrow) given by the 3D-CBIST model are shown to be considerably lower than {phi} = 1.0 assumed under the ICRP Publication 30 and 2003 Eckerman bone models. For example, values of absorbed fraction for the self-dose to active bone marrow in the ribs, cervical vertebra, and parietal bone are 0.81, 0.80, and 0.55 for 6-MeV {alpha}-particles and are 0.74, 0.72, and 0.43 for 9-MeV {alpha}-particles, where each is evaluated at ICRP reference cellularities in the 3D-CBIST model (72%, 72%, and 42%, respectively, at age 25 y). Conclusion: Improvements in patient-specific dosimetry of skeletal tissues require explicit consideration of not only changes in target mass with variable patient marrow cellularity (i.e., active marrow) but also corresponding changes in values of the absorbed fraction. The data given in this study provide a more-firm basis for application of the MIRD schema to patient-specific dosimetry for newly developing therapies using {alpha}-particle emitters.

Key Words: radionuclide therapy • {alpha}-particles • absorbed fraction • marrow cellularity • bone dosimetry.




This article has been cited by other articles:


Home page
JNMHome page
G. Sgouros, J. C. Roeske, M. R. McDevitt, S. Palm, B. J. Allen, D. R. Fisher, A. B. Brill, H. Song, R. W. Howell, G. Akabani, et al.
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of {alpha}-Particle Emitters for Targeted Radionuclide Therapy
J. Nucl. Med., February 1, 2010; 51(2): 311 - 328.
[Abstract] [Full Text] [PDF]


Home page
Radiat Prot DosimetryHome page
J. G. Hunt, C. J. Watchman, and W. E. Bolch
Calculation of absorbed fractions to human skeletal tissues due to alpha particles using the Monte Carlo and 3-d chord-based transport techniques
Radiat Prot Dosimetry, November 1, 2007; 127(1-4): 223 - 226.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
G. Sgouros
Toward Patient-Friendly Cell-Level Dosimetry
J. Nucl. Med., April 1, 2007; 48(4): 496 - 497.
[Full Text] [PDF]


Home page
JNMHome page
J. M. Brindle, A. A. Trindade, A. P. Shah, D. W. Jokisch, P. W. Patton, J. C. Pichardo, and W. E. Bolch
Linear Regression Model for Predicting Patient-Specific Total Skeletal Spongiosa Volume for Use in Molecular Radiotherapy Dosimetry
J. Nucl. Med., November 1, 2006; 47(11): 1875 - 1883.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.